StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 04 Mar 2026 21:48:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Form 4 ENDRA Life Sciences Inc. For: Mar 02 Filed by: Jacroux Richard http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Mar+02++Filed+by%3A+Jacroux+Richard/26113792.html si-local-file:///var/storage/secattach/20260304/26113792.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Mar+02++Filed+by%3A+Jacroux+Richard/26113792.html Wed, 04 Mar 2026 21:48:00 -0500 NDRA O.30741434 Form 4 ENDRA Life Sciences Inc. For: Mar 02 Filed by: Jacroux Richard http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Mar+02++Filed+by%3A+Jacroux+Richard/26113792.html si-local-file:///var/storage/secattach/20260304/26113792.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Mar+02++Filed+by%3A+Jacroux+Richard/26113792.html Wed, 04 Mar 2026 21:48:00 -0500 NDRA O.30741434 Form 4 ENDRA Life Sciences Inc. For: Mar 02 Filed by: Tokman Alexander Y http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Mar+02++Filed+by%3A+Tokman+Alexander+Y/26113793.html si-local-file:///var/storage/secattach/20260304/26113793.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Mar+02++Filed+by%3A+Tokman+Alexander+Y/26113793.html Wed, 04 Mar 2026 21:48:00 -0500 NDRA O.30741434 Form 4 ENDRA Life Sciences Inc. For: Mar 02 Filed by: Tokman Alexander Y http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Mar+02++Filed+by%3A+Tokman+Alexander+Y/26113793.html si-local-file:///var/storage/secattach/20260304/26113793.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Mar+02++Filed+by%3A+Tokman+Alexander+Y/26113793.html Wed, 04 Mar 2026 21:48:00 -0500 NDRA O.30741434 ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care http://www.streetinsider.com/Press+Releases/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html <p class="bwalignc"> <i>Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators</i> </p> <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <b>ENDRA Life Sciences Inc. (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device’s robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frontiersin.org%2Fjournals%2Fmedicine%2Farticles%2F10.3389%2Ffmed.2025.1618275%2Ffull&esheet=54432864&newsitemid=20260226198097&lan=en-US&anchor=30%25+of+adults&index=1&md5=6b9bf43c6cc685ff841e367e04022b13" http://www.streetinsider.com/Press+Releases/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html Thu, 26 Feb 2026 08:00:00 -0500 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care http://www.streetinsider.com/Press+Releases/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html <p class="bwalignc"> <i>Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators</i> </p> <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <b>ENDRA Life Sciences Inc. (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device’s robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frontiersin.org%2Fjournals%2Fmedicine%2Farticles%2F10.3389%2Ffmed.2025.1618275%2Ffull&esheet=54432864&newsitemid=20260226198097&lan=en-US&anchor=30%25+of+adults&index=1&md5=6b9bf43c6cc685ff841e367e04022b13" http://www.streetinsider.com/Press+Releases/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html Thu, 26 Feb 2026 08:00:00 -0500 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care http://www.streetinsider.com/Press+Releases/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html <p class="bwalignc"> <i>Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators</i> </p> <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <b>ENDRA Life Sciences Inc. (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device’s robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frontiersin.org%2Fjournals%2Fmedicine%2Farticles%2F10.3389%2Ffmed.2025.1618275%2Ffull&esheet=54432864&newsitemid=20260226198097&lan=en-US&anchor=30%25+of+adults&index=1&md5=6b9bf43c6cc685ff841e367e04022b13" http://www.streetinsider.com/Press+Releases/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html Thu, 26 Feb 2026 08:00:00 -0500 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care http://www.streetinsider.com/Press+Releases/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html <p class="bwalignc"> <i>Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators</i> </p> <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <b>ENDRA Life Sciences Inc. (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device’s robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frontiersin.org%2Fjournals%2Fmedicine%2Farticles%2F10.3389%2Ffmed.2025.1618275%2Ffull&esheet=54432864&newsitemid=20260226198097&lan=en-US&anchor=30%25+of+adults&index=1&md5=6b9bf43c6cc685ff841e367e04022b13" http://www.streetinsider.com/Press+Releases/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html Thu, 26 Feb 2026 08:00:00 -0500 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care http://www.streetinsider.com/Press+Releases/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html <p class="bwalignc"> <i>Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators</i> </p> <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <b>ENDRA Life Sciences Inc. (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device’s robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frontiersin.org%2Fjournals%2Fmedicine%2Farticles%2F10.3389%2Ffmed.2025.1618275%2Ffull&esheet=54432864&newsitemid=20260226198097&lan=en-US&anchor=30%25+of+adults&index=1&md5=6b9bf43c6cc685ff841e367e04022b13" http://www.streetinsider.com/Press+Releases/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html Thu, 26 Feb 2026 08:00:00 -0500 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care http://www.streetinsider.com/Press+Releases/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html <p class="bwalignc"> <i>Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators</i> </p> <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <b>ENDRA Life Sciences Inc. (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device’s robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frontiersin.org%2Fjournals%2Fmedicine%2Farticles%2F10.3389%2Ffmed.2025.1618275%2Ffull&esheet=54432864&newsitemid=20260226198097&lan=en-US&anchor=30%25+of+adults&index=1&md5=6b9bf43c6cc685ff841e367e04022b13" http://www.streetinsider.com/Press+Releases/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html Thu, 26 Feb 2026 08:00:00 -0500 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care http://www.streetinsider.com/Business+Wire/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html <p class="bwalignc"> <i>Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators</i> </p> <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <b>ENDRA Life Sciences Inc. (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device’s robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frontiersin.org%2Fjournals%2Fmedicine%2Farticles%2F10.3389%2Ffmed.2025.1618275%2Ffull&esheet=54432864&newsitemid=20260226198097&lan=en-US&anchor=30%25+of+adults&index=1&md5=6b9bf43c6cc685ff841e367e04022b13" http://www.streetinsider.com/Business+Wire/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html Thu, 26 Feb 2026 08:00:00 -0500 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care http://www.streetinsider.com/Business+Wire/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html <p class="bwalignc"> <i>Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators</i> </p> <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <b>ENDRA Life Sciences Inc. (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device’s robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frontiersin.org%2Fjournals%2Fmedicine%2Farticles%2F10.3389%2Ffmed.2025.1618275%2Ffull&esheet=54432864&newsitemid=20260226198097&lan=en-US&anchor=30%25+of+adults&index=1&md5=6b9bf43c6cc685ff841e367e04022b13" http://www.streetinsider.com/Business+Wire/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html Thu, 26 Feb 2026 08:00:00 -0500 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care http://www.streetinsider.com/Business+Wire/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html <p class="bwalignc"> <i>Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators</i> </p> <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <b>ENDRA Life Sciences Inc. (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device’s robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frontiersin.org%2Fjournals%2Fmedicine%2Farticles%2F10.3389%2Ffmed.2025.1618275%2Ffull&esheet=54432864&newsitemid=20260226198097&lan=en-US&anchor=30%25+of+adults&index=1&md5=6b9bf43c6cc685ff841e367e04022b13" http://www.streetinsider.com/Business+Wire/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html Thu, 26 Feb 2026 08:00:00 -0500 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care http://www.streetinsider.com/Business+Wire/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html <p class="bwalignc"> <i>Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators</i> </p> <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <b>ENDRA Life Sciences Inc. (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device’s robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frontiersin.org%2Fjournals%2Fmedicine%2Farticles%2F10.3389%2Ffmed.2025.1618275%2Ffull&esheet=54432864&newsitemid=20260226198097&lan=en-US&anchor=30%25+of+adults&index=1&md5=6b9bf43c6cc685ff841e367e04022b13" http://www.streetinsider.com/Business+Wire/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html Thu, 26 Feb 2026 08:00:00 -0500 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care http://www.streetinsider.com/Business+Wire/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html <p class="bwalignc"> <i>Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators</i> </p> <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <b>ENDRA Life Sciences Inc. (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device’s robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frontiersin.org%2Fjournals%2Fmedicine%2Farticles%2F10.3389%2Ffmed.2025.1618275%2Ffull&esheet=54432864&newsitemid=20260226198097&lan=en-US&anchor=30%25+of+adults&index=1&md5=6b9bf43c6cc685ff841e367e04022b13" http://www.streetinsider.com/Business+Wire/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html Thu, 26 Feb 2026 08:00:00 -0500 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care http://www.streetinsider.com/Business+Wire/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html <p class="bwalignc"> <i>Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators</i> </p> <p> ANN ARBOR, Mich.--(BUSINESS WIRE)-- <b>ENDRA Life Sciences Inc. (NASDAQ: NDRA)</b> (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device’s robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.frontiersin.org%2Fjournals%2Fmedicine%2Farticles%2F10.3389%2Ffmed.2025.1618275%2Ffull&esheet=54432864&newsitemid=20260226198097&lan=en-US&anchor=30%25+of+adults&index=1&md5=6b9bf43c6cc685ff841e367e04022b13" http://www.streetinsider.com/Business+Wire/ENDRA%E2%80%99s+TAEUS%C2%AE+Liver+Device+Demonstrates+High-Level+Consistency+in+Clinical+Study%2C+Delivering+MRI-Level+Results+at+the+Point+of+Patient+Care/26064689.html Thu, 26 Feb 2026 08:00:00 -0500 A.06822034 A.19717950 NDRA O.04746846 O.20026344 O.30741434 Form 4 ENDRA Life Sciences Inc. For: Jan 21 Filed by: Harsh Michael http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Jan+21++Filed+by%3A+Harsh+Michael/25888659.html si-local-file:///var/storage/secattach/20260123/25888659.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Jan+21++Filed+by%3A+Harsh+Michael/25888659.html Fri, 23 Jan 2026 19:44:00 -0500 NDRA O.30741434 Form 4 ENDRA Life Sciences Inc. For: Jan 21 Filed by: Harsh Michael http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Jan+21++Filed+by%3A+Harsh+Michael/25888659.html si-local-file:///var/storage/secattach/20260123/25888659.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Jan+21++Filed+by%3A+Harsh+Michael/25888659.html Fri, 23 Jan 2026 19:44:00 -0500 NDRA O.30741434 Form 4 ENDRA Life Sciences Inc. For: Jan 21 Filed by: DIGIANDOMENICO ANTHONY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Jan+21++Filed+by%3A+DIGIANDOMENICO+ANTHONY/25888661.html si-local-file:///var/storage/secattach/20260123/25888661.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Jan+21++Filed+by%3A+DIGIANDOMENICO+ANTHONY/25888661.html Fri, 23 Jan 2026 19:44:00 -0500 NDRA O.30741434 Form 4 ENDRA Life Sciences Inc. For: Jan 21 Filed by: DIGIANDOMENICO ANTHONY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Jan+21++Filed+by%3A+DIGIANDOMENICO+ANTHONY/25888661.html si-local-file:///var/storage/secattach/20260123/25888661.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Jan+21++Filed+by%3A+DIGIANDOMENICO+ANTHONY/25888661.html Fri, 23 Jan 2026 19:44:00 -0500 NDRA O.30741434 Form 4 ENDRA Life Sciences Inc. For: Jan 21 Filed by: Tokman Alexander Y http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Jan+21++Filed+by%3A+Tokman+Alexander+Y/25888655.html si-local-file:///var/storage/secattach/20260123/25888655.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Jan+21++Filed+by%3A+Tokman+Alexander+Y/25888655.html Fri, 23 Jan 2026 19:43:00 -0500 NDRA O.30741434 Form 4 ENDRA Life Sciences Inc. For: Jan 21 Filed by: Tokman Alexander Y http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Jan+21++Filed+by%3A+Tokman+Alexander+Y/25888655.html si-local-file:///var/storage/secattach/20260123/25888655.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Jan+21++Filed+by%3A+Tokman+Alexander+Y/25888655.html Fri, 23 Jan 2026 19:43:00 -0500 NDRA O.30741434 Form 4 ENDRA Life Sciences Inc. For: Jan 21 Filed by: Basenese Lou http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Jan+21++Filed+by%3A+Basenese+Lou/25888657.html si-local-file:///var/storage/secattach/20260123/25888657.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Jan+21++Filed+by%3A+Basenese+Lou/25888657.html Fri, 23 Jan 2026 19:43:00 -0500 NDRA O.30741434 Form 4 ENDRA Life Sciences Inc. For: Jan 21 Filed by: Basenese Lou http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Jan+21++Filed+by%3A+Basenese+Lou/25888657.html si-local-file:///var/storage/secattach/20260123/25888657.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Jan+21++Filed+by%3A+Basenese+Lou/25888657.html Fri, 23 Jan 2026 19:43:00 -0500 NDRA O.30741434 Form 4 ENDRA Life Sciences Inc. For: Jan 21 Filed by: Jacroux Richard http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Jan+21++Filed+by%3A+Jacroux+Richard/25888658.html si-local-file:///var/storage/secattach/20260123/25888658.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ENDRA+Life+Sciences+Inc.++For%3A+Jan+21++Filed+by%3A+Jacroux+Richard/25888658.html Fri, 23 Jan 2026 19:43:00 -0500 NDRA O.30741434